marketcaparena
Search

    JAZZ

    Jazz Pharmaceuticals plc

    Company overview

    Market capitalization
    $15.47B
    Employees
    2,890
    Latest publication
    2026-09-29
    About Jazz Pharmaceuticals plc

    Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Total Revenue1,208,300,000USD1,068,900,000USD1,197,926,000USD1,126,107,000USD1,088,173,000USD1,054,969,000USD1,023,825,000USD901,983,000USD
    Cost Of Revenue363,400,000USD306,400,000USD24,648,000USD257,760,000USD128,713,000USD111,611,000USD109,902,000USD95,487,000USD
    Gross Profit844,900,000USD762,500,000USD1,173,278,000USD868,347,000USD959,460,000USD943,358,000USD913,923,000USD806,496,000USD
    Research Development207,500,000USD134,100,000USD171,409,000USD240,703,000USD240,500,000USD199,919,000USD220,734,000USD222,847,000USD
    Selling General Administrative389,200,000USD352,700,000USD406,212,000USD530,647,000USD369,287,000USD325,772,000USD338,523,000USD351,712,000USD
    Total Operating Expenses596,700,000USD548,700,000USD264,082,000USD810,838,000USD768,690,000USD683,148,000USD714,480,000USD740,289,000USD
    Operating Income248,200,000USD213,800,000USD909,196,000USD57,509,000USD190,770,000USD260,210,000USD199,443,000USD66,207,000USD
    Total Other Income Expense Net-37,200,000USD85,400,000USD-700,915,000USD-48,474,000USD-57,567,000USD-59,687,999USD-61,528,000USD-69,155,999USD
    Interest Income25,300,000USD———————
    Income Before Tax211,000,000USD299,200,000USD208,281,000USD9,035,000USD133,203,000USD200,522,000USD137,915,000USD-2,949,000USD
    Income Tax Expense18,100,000USD6,100,000USD4,877,000USD-242,424,000USD-57,912,000USD-14,533,000USD-30,653,000USD11,669,000USD
    Equity Method Income Loss-100,000USD———————
    Net Income192,800,000USD293,100,000USD203,451,000USD251,412,000USD191,115,000USD215,055,000USD168,568,000USD-14,618,000USD
    Unclassified Operating Expenses—61,900,000USD-313,539,000USD39,488,000USD158,903,000USD157,457,000USD155,223,000USD165,730,000USD
    Interest Expense—63,300,000USD45,406,000USD48,576,000USD51,256,000USD58,702,000USD62,023,000USD66,116,000USD
    Net Interest Income—-39,900,000USD-45,406,000USD-48,576,000USD-51,256,000USD-58,702,000USD-62,023,000USD-66,116,000USD
    Tax Provision—6,100,000USD4,963,000USD-242,424,000USD-57,912,000USD-14,533,000USD-30,653,000USD11,669,000USD
    Net Income From Continuing Ops—293,100,000USD203,451,000USD251,412,000USD191,115,000USD215,055,000USD168,568,000USD-14,618,000USD
    Ebit—362,500,000USD253,687,000USD57,611,000USD228,564,000USD259,224,000USD199,938,000USD105,150,000USD
    Ebitda—543,900,000USD278,559,000USD235,857,000USD396,981,000USD424,456,000USD362,973,000USD268,533,000USD
    Depreciation And Amortization—181,400,000USD24,872,000USD178,246,000USD168,417,000USD165,232,000USD163,035,000USD163,383,000USD
    Reconciled Depreciation—181,400,000USD179,169,000USD178,246,000USD168,417,000USD165,232,000USD163,035,000USD163,383,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USDFY 20172017-12-31 · USD
    Total Revenue4,267,586,000USD4,068,950,000USD3,834,204,000USD3,094,238,000USD2,363,567,000USD2,161,761,000USD1,890,922,000USD1,618,693,000USD
    Cost Of Revenue503,296,000USD445,713,000USD435,577,000USD440,760,000USD148,917,000USD127,930,000USD121,544,000USD110,188,000USD
    Gross Profit3,764,290,000USD3,623,237,000USD3,398,627,000USD2,653,478,000USD2,214,650,000USD2,033,831,000USD1,769,378,000USD1,508,505,000USD
    Research Development782,736,000USD884,000,000USD849,658,000USD505,748,000USD335,375,000USD299,726,000USD226,616,000USD198,442,000USD
    Selling General Administrative1,809,271,000USD1,385,294,000USD1,330,274,000USD1,451,683,000USD854,233,000USD736,942,000USD683,530,000USD544,142,000USD
    Unclassified Operating Expenses947,862,000USD637,313,000USD640,115,000USD525,769,000USD646,969,000USD464,789,000USD244,394,000USD237,079,000USD
    Total Operating Expenses3,539,869,000USD2,906,607,000USD2,820,047,000USD2,483,200,000USD1,836,577,000USD1,501,457,000USD1,154,540,000USD979,663,000USD
    Operating Income224,421,000USD716,630,000USD578,580,000USD170,278,000USD378,073,000USD532,374,000USD614,838,000USD528,842,000USD
    Interest Expense195,051,000USD238,097,000USD289,438,000USD278,766,000USD99,707,000USD72,261,000USD78,500,000USD77,756,000USD
    Net Interest Income-195,051,000USD-238,097,000USD-293,239,000USD-278,766,000USD-99,707,000USD-72,261,000USD-77,075,000USD-77,756,000USD
    Income Before Tax-628,591,000USD468,691,000USD294,920,000USD-113,552,000USD272,133,000USD450,213,000USD527,260,000USD440,108,000USD
    Income Tax Expense-272,443,000USD-91,429,000USD-119,912,000USD216,116,000USD33,517,000USD-73,154,000USD80,162,000USD-47,740,000USD
    Tax Provision-272,443,000USD-91,429,000USD-186,865,000USD216,116,000USD33,517,000USD-73,154,000USD80,162,000USD-47,740,000USD
    Net Income-356,148,000USD560,120,000USD414,832,000USD-328,954,000USD238,616,000USD523,367,000USD447,098,000USD487,848,000USD
    Net Income From Continuing Ops-356,148,000USD560,120,000USD79,954,000USD-329,668,000USD241,578,000USD523,367,000USD449,301,000USD488,817,000USD
    Ebit-433,540,000USD861,644,000USD810,726,000USD475,263,000USD765,461,999USD642,349,000USD715,934,000USD613,842,000USD
    Ebitda108,460,000USD1,521,711,000USD1,449,422,000USD1,027,746,000USD1,043,714,999USD1,012,505,000USD932,665,000USD778,996,000USD
    Depreciation And Amortization542,000,000USD660,067,000USD638,696,000USD552,483,000USD278,253,000USD370,156,000USD216,731,000USD165,154,000USD
    Reconciled Depreciation696,297,000USD660,067,000USD624,226,000USD552,483,000USD278,253,000USD370,156,000USD216,731,000USD165,154,000USD
    Total Other Income Expense Net-853,012,000USD-247,939,000USD-283,660,000USD-283,830,000USD-105,940,000USD-82,161,000USD-87,578,000USD-88,734,000USD
    Non Operating Income Net Other———-5,064,000USD-6,233,000USD—-9,078,000USD-10,978,000USD
    Net Income Applicable To Common Shares———-329,668,000USD238,616,000USD523,367,000USD447,098,000USD487,848,000USD
    Interest Income—————82,161,000USD86,153,000USD88,734,000USD
    Minority Interest———————0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets11,080,900,000USD11,859,600,000USD11,659,340,000USD11,356,485,000USD10,944,141,000USD11,534,682,000USD12,012,257,000USD12,255,716,000USD
    Cash And Equivalents1,619,800,000USD———————
    Cash And Short Term Investments2,199,800,000USD2,874,300,000USD2,441,899,000USD2,046,070,000USD1,669,880,000USD2,571,946,000USD2,992,864,000USD2,618,135,000USD
    Total Current Assets3,968,200,000USD4,583,100,000USD4,166,043,000USD3,755,878,000USD3,350,433,000USD4,127,817,000USD4,629,028,000USD4,390,423,000USD
    Other Current Assets244,500,000USD435,000,000USD476,435,000USD462,333,000USD461,560,000USD410,103,000USD438,954,000USD509,347,000USD
    Other Non Current Assets86,300,000USD———————
    Total Liabilities6,279,200,000USD———————
    Total Current Liabilities2,230,800,000USD2,246,600,000USD2,242,521,000USD2,274,102,000USD2,071,205,000USD1,222,610,000USD1,038,573,000USD1,029,977,000USD
    Other Current Liabilities1,030,000,000USD———————
    Other Non Current Liabilities140,900,000USD———————
    Total Stockholder Equity4,801,700,000USD4,532,300,000USD4,318,584,000USD3,959,030,000USD3,706,359,000USD4,174,891,000USD4,093,756,000USD4,171,067,000USD
    Total Equity Including Noncontrolling Interest4,801,700,000USD———————
    Short Long Term Debt2,032,800,000USD1,030,500,000USD1,029,903,000USD1,029,179,000USD1,028,478,000USD31,000,000USD31,000,000USD31,000,000USD
    Long Term Debt3,335,000,000USD4,324,200,000USD4,328,354,000USD4,331,982,000USD4,335,616,000USD5,336,481,000USD6,077,640,000USD6,080,802,000USD
    Net Receivables880,900,000USD836,300,000USD830,747,000USD764,364,000USD714,004,000USD652,992,000USD716,765,000USD723,639,000USD
    Inventory443,000,000USD437,500,000USD416,962,000USD483,111,000USD504,989,000USD492,776,000USD480,445,000USD539,302,000USD
    Property Plant Equipment Net264,100,000USD258,900,000USD258,737,000USD250,117,000USD248,057,000USD228,050,000USD226,995,000USD253,586,000USD
    Goodwill1,799,800,000USD———————
    Intangible Assets4,029,500,000USD4,203,800,000USD4,429,510,000USD4,565,737,000USD4,768,987,000USD4,718,158,000USD4,755,695,000USD5,144,217,000USD
    Accounts Payable128,500,000USD100,000,000USD122,061,000USD152,227,000USD89,366,000USD95,930,000USD77,869,000USD85,425,000USD
    Common Stock0USD100,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD
    Retained Earnings1,132,000,000USD939,200,000USD646,176,000USD442,725,000USD191,313,000USD1,034,806,000USD1,127,347,000USD936,232,000USD
    Accumulated Other Comprehensive Income-662,500,000USD-651,000,000USD-568,598,000USD-569,425,000USD-485,768,000USD-785,610,000USD-947,667,000USD-603,397,000USD
    Total Liab—7,327,300,000USD7,340,756,000USD7,397,455,000USD7,237,782,000USD7,359,791,000USD7,918,501,000USD8,084,649,000USD
    Other Current Liab—1,007,500,000USD1,019,453,000USD1,078,758,000USD860,928,000USD1,050,474,000USD896,168,000USD839,475,000USD
    Capital Stock—100,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD
    Good Will—1,805,000,000USD1,829,340,000USD1,827,483,000USD1,843,974,000USD1,760,045,000USD1,716,323,000USD1,804,646,000USD
    Cash—1,844,300,000USD1,391,899,000USD1,236,070,000USD1,189,880,000USD1,861,946,000USD2,412,864,000USD2,218,135,000USD
    Net Debt—3,572,600,000USD4,031,967,000USD4,192,455,000USD4,243,204,000USD3,557,759,000USD3,749,493,000USD3,983,885,000USD
    Short Term Debt—1,045,400,000USD1,044,620,000USD1,043,117,000USD1,042,361,000USD44,444,000USD45,779,000USD50,103,000USD
    Short Long Term Debt Total—5,416,900,000USD5,423,866,000USD5,428,525,000USD5,433,084,000USD5,419,705,000USD6,162,357,000USD6,202,020,000USD
    Short Term Investments—1,030,000,000USD1,050,000,000USD810,000,000USD480,000,000USD710,000,000USD580,000,000USD400,000,000USD
    Property Plant Equipment Gross—440,600,000USD437,290,000USD421,330,000USD414,381,000USD399,614,000USD388,952,000USD410,400,000USD
    Common Stock Shares Outstanding—66,099,999shares60,984,246shares61,606,000shares61,194,000shares60,979,000shares61,503,000shares63,174,000shares
    Non Current Assets Total—7,276,500,000USD7,493,297,000USD7,600,607,000USD7,593,708,000USD7,406,865,000USD7,383,229,000USD7,865,293,000USD
    Non Current Liabilities Total—5,080,700,000USD5,098,235,000USD5,123,353,000USD5,166,577,000USD6,137,181,000USD6,879,928,000USD7,054,672,000USD
    Non Current Liabilities Other—161,500,000USD124,519,000USD108,912,000USD93,731,000USD91,119,000USD86,614,000USD110,971,000USD
    Non Currrent Assets Other—101,800,000USD106,580,000USD106,802,000USD125,487,000USD125,515,000USD123,971,000USD79,626,000USD
    Net Working Capital—2,336,500,000USD1,923,522,000USD1,481,776,000USD1,279,228,000USD2,905,207,000USD3,590,455,000USD3,360,446,000USD
    Unclassified Non Current Assets—907,000,000USD869,130,000USD850,468,000USD607,203,000USD575,097,000USD560,245,000USD583,218,000USD
    Unclassified Current Liabilities—-936,800,000USD-973,516,000USD-1,029,179,000USD-949,928,000USD—-12,243,000USD-31,000,000USD
    Unclassified Non Current Liabilities—595,000,000USD645,362,000USD682,459,000USD737,230,000USD709,581,000USD715,674,000USD862,899,000USD
    Unclassified Equity—4,243,900,000USD4,240,884,000USD4,085,608,000USD4,000,692,000USD3,925,573,000USD3,913,954,000USD3,838,110,000USD
    Current Deferred Revenue———————54,974,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets11,659,340,000USD12,012,257,000USD11,393,359,000USD10,835,255,000USD12,298,639,000USD6,535,901,000USD5,538,897,000USD5,203,491,000USD
    Intangible Assets4,429,510,000USD4,755,695,000USD5,418,039,000USD5,794,437,000USD7,152,328,000USD2,195,051,000USD2,440,977,000USD2,731,334,000USD
    Other Current Assets476,435,000USD438,954,000USD506,285,000USD359,104,000USD383,805,000USD214,913,000USD118,329,000USD92,589,000USD
    Total Liab7,340,756,000USD7,918,501,000USD7,656,362,000USD7,749,521,000USD8,333,448,000USD2,876,156,000USD2,427,916,000USD2,446,069,000USD
    Total Stockholder Equity4,318,584,000USD4,093,756,000USD3,736,997,000USD3,085,734,000USD3,965,191,000USD3,659,745,000USD3,110,981,000USD2,757,422,000USD
    Other Current Liab1,019,453,000USD896,168,000USD774,467,000USD787,317,000USD650,541,000USD338,275,000USD255,145,000USD264,887,000USD
    Common Stock6,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD
    Capital Stock61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD61,000USD
    Retained Earnings646,176,000USD1,127,347,000USD878,656,000USD733,586,000USD830,226,000USD1,159,894,000USD1,067,815,000USD841,050,000USD
    Good Will1,829,340,000USD1,716,323,000USD1,753,130,000USD1,692,662,000USD1,827,609,000USD958,303,000USD920,018,000USD927,630,000USD
    Cash1,391,899,000USD2,412,864,000USD1,506,310,000USD881,482,000USD591,448,000USD1,057,769,000USD637,344,000USD309,622,000USD
    Cash And Short Term Investments2,441,899,000USD2,992,864,000USD1,626,310,000USD881,482,000USD591,448,000USD2,132,769,000USD1,077,344,000USD824,622,000USD
    Total Current Assets4,166,043,000USD4,629,028,000USD3,435,428,000USD2,606,140,000USD2,611,334,000USD2,839,568,000USD1,630,268,000USD1,234,005,000USD
    Total Current Liabilities2,242,521,000USD1,038,573,000USD1,536,692,000USD933,193,000USD809,303,000USD653,745,000USD364,490,000USD345,487,000USD
    Net Debt4,031,967,000USD3,749,493,000USD4,285,304,000USD4,930,635,000USD5,561,458,000USD1,191,561,000USD1,133,867,000USD1,286,790,000USD
    Short Term Debt1,044,620,000USD45,779,000USD624,401,000USD46,938,000USD46,763,000USD260,779,000USD46,115,000USD33,387,000USD
    Short Long Term Debt1,029,903,000USD31,000,000USD604,954,000USD31,000,000USD31,000,000USD246,322,000USD33,387,000USD33,387,000USD
    Short Long Term Debt Total5,423,866,000USD6,162,357,000USD5,791,614,000USD5,812,117,000USD6,152,906,000USD2,249,330,000USD1,771,211,000USD1,596,412,000USD
    Long Term Debt4,328,354,000USD6,077,640,000USD5,107,988,000USD5,693,341,000USD6,018,943,000USD1,848,516,000USD1,573,870,000USD1,563,025,000USD
    Short Term Investments1,050,000,000USD580,000,000USD120,000,000USD30,000,000USD0USD1,075,000,000USD440,000,000USD515,000,000USD
    Net Receivables830,747,000USD716,765,000USD705,794,000USD651,493,000USD563,360,000USD396,490,000USD355,987,000USD263,838,000USD
    Inventory416,962,000USD480,445,000USD597,039,000USD714,061,000USD1,072,721,000USD95,396,000USD78,608,000USD52,956,000USD
    Accounts Payable122,061,000USD77,869,000USD102,750,000USD90,758,000USD100,298,000USD26,945,000USD47,545,000USD40,602,000USD
    Property Plant Equipment Net258,737,000USD226,995,000USD234,986,000USD301,376,000USD343,423,000USD257,104,000USD270,891,000USD200,358,000USD
    Property Plant Equipment Gross437,290,000USD388,952,000USD368,337,000USD301,376,000USD343,423,000USD257,104,000USD270,891,000USD200,358,000USD
    Accumulated Other Comprehensive Income-568,598,000USD-947,667,000USD-842,147,000USD-1,125,509,000USD-400,360,000USD-134,352,000USD-223,393,000USD-197,791,000USD
    Common Stock Shares Outstanding60,984,246shares66,007,000shares72,066,000shares62,539,000shares59,694,000shares56,517,000shares57,550,000shares61,221,000shares
    Non Current Assets Total7,493,297,000USD7,383,229,000USD7,957,931,000USD8,229,115,000USD9,687,305,000USD3,696,333,000USD3,908,629,000USD3,969,486,000USD
    Non Current Liabilities Total5,098,235,000USD6,879,928,000USD6,119,670,000USD6,816,328,000USD7,524,145,000USD2,222,411,000USD2,063,426,000USD2,100,582,000USD
    Non Current Liabilities Other124,519,000USD86,614,000USD104,751,000USD106,812,000USD116,998,000USD101,148,000USD109,374,000USD218,879,000USD
    Non Currrent Assets Other106,580,000USD119,639,000USD73,942,000USD435,140,000USD358,945,000USD30,959,000USD55,340,000USD52,285,000USD
    Net Working Capital1,923,522,000USD3,590,455,000USD1,898,736,000USD1,672,947,000USD1,802,031,000USD2,185,823,000USD1,265,778,000USD888,518,000USD
    Unclassified Non Current Assets869,130,000USD564,577,000USD306,327,000USD-429,640,000USD-358,945,000USD-160,128,000USD-55,340,000USD-52,285,000USD
    Unclassified Current Liabilities-973,516,000USD-12,243,000USD-685,948,000USD-23,283,000USD-21,392,000USD-221,122,000USD-22,422,000USD-32,190,000USD
    Unclassified Non Current Liabilities645,362,000USD715,674,000USD906,931,000USD-974,101,000USD—-91,510,000USD35,086,000USD-527,976,000USD
    Unclassified Equity4,240,939,000USD3,913,954,000USD3,700,366,000USD3,477,535,000USD3,535,203,000USD2,634,081,000USD2,266,437,000USD2,114,041,000USD
    Other Assets——171,507,000USD435,140,000USD363,945,000USD415,044,000USD272,243,000USD103,523,000USD
    Current Deferred Revenue——116,068,000USD463,000USD2,093,000USD2,546,000USD4,720,000USD5,414,000USD
    Deferred Long Term Liab———944,337,000USD12,029,000USD130,397,000USD7,426,000USD309,097,000USD
    Other Liab———1,045,939,000USD1,418,002,000USD233,860,000USD337,670,000USD537,557,000USD
    Net Tangible Assets———-4,329,527,000USD-5,014,746,000USD648,741,000USD-250,014,000USD-891,961,000USD
    Unclassified Current Assets———-30,000,000USD————
    Long Term Investments——————4,500,000USD6,641,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation360,500,000USD
    Stock Based Compensation147,800,000USD
    Deferred Income Tax-104,900,000USD
    Other Non Cash Items-1,500,000USD
    Change To Account Receivables-51,400,000USD
    Change To Inventory-107,700,000USD
    Change To Liabilities-3,900,000USD
    Change In Working Capital-107,100,000USD
    Operating Cash Flow823,900,000USD
    Capital Expenditures-37,800,000USD
    Net Investments470,000,000USD
    Unclassified Investing Cash Flow45,800,000USD
    Investing Cash Flow478,000,000USD
    Common Stock Issuance55,600,000USD
    Net Common Stock Issuance-113,100,000USD
    Unclassified Financing Cash Flow-1,015,500,000USD
    Financing Cash Flow-1,073,000,000USD
    Effect Of Forex Changes On Cash-1,000,000USD
    Change In Cash227,900,000USD
    End Cash Flow1,619,800,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USDQ1 20242024-03-31 · USD
    Net Income293,100,000USD251,412,000USD-718,470,000USD-92,541,000USD191,115,000USD215,055,000USD168,568,000USD-14,618,000USD
    Depreciation181,400,000USD178,246,000USD174,009,000USD164,873,000USD168,417,000USD165,232,000USD163,035,000USD163,383,000USD
    Stock Based Compensation74,500,000USD88,125,000USD64,501,000USD67,653,000USD70,190,000USD59,760,000USD56,654,000USD61,441,000USD
    Other Non Cash Items-62,500,000USD97,393,000USD962,350,000USD45,728,000USD51,145,000USD49,486,000USD45,084,000USD67,008,000USD
    Change To Account Receivables-6,500,000USD-50,996,000USD-55,519,000USD66,049,000USD864,000USD-22,256,000USD8,720,000USD-8,443,000USD
    Change To Inventory-77,800,000USD-31,909,000USD-26,231,000USD-35,621,000USD-18,665,000USD-9,286,000USD-4,747,000USD-12,844,000USD
    Change In Working Capital-12,100,000USD130,850,000USD-327,116,000USD287,904,000USD-79,932,000USD-26,382,000USD-26,806,000USD56,400,000USD
    Total Cash From Operating Activities408,200,000USD474,616,000USD88,855,000USD429,784,000USD398,580,000USD398,747,000USD331,352,000USD267,228,999USD
    Capital Expenditures-19,700,000USD-15,175,000USD12,033,000USD-38,881,000USD-13,287,000USD-10,788,000USD-7,091,000USD-6,903,999USD
    Free Cash Flow388,500,000USD459,441,000USD100,888,000USD390,903,000USD385,293,000USD387,959,000USD324,261,000USD260,325,000USD
    Investments220,000,000USD-327,800,000USD-641,020,000USD-168,931,000USD-193,287,000USD214,087,000USD-257,091,000USD-271,904,000USD
    Total Cashflows From Investing Activities123,100,000USD-327,800,000USD-641,020,000USD-168,931,000USD-193,287,000USD214,087,000USD-257,091,000USD-271,904,000USD
    Net Borrowings-7,800,000USD-7,750,000USD-7,750,000USD-757,750,000USD-7,750,000USD398,017,000USD——
    Total Cash From Financing Activities-78,500,000USD-10,829,000USD-124,525,000USD-813,466,000USD-8,275,000USD246,428,000USD-161,085,000USD-56,552,000USD
    Change In Cash452,400,000USD46,190,000USD-672,066,000USD-550,918,000USD234,729,000USD862,333,000USD62,417,000USD27,075,000USD
    Begin Period Cash Flow1,391,900,000USD1,189,880,000USD1,861,946,000USD2,412,864,000USD1,968,135,000USD1,355,802,000USD1,233,385,000USD1,206,310,000USD
    End Period Cash Flow1,844,300,000USD1,236,070,000USD1,189,880,000USD1,861,946,000USD2,202,864,000USD2,218,135,000USD1,295,802,000USD1,233,385,000USD
    Other Cashflows From Investing Activities-77,200,000USD-42,500,000USD-680,050,000USD-25,000,000USD—-835,125,000USD-250,000,000USD-10,000,000USD
    Other Cashflows From Financing Activities-103,600,000USD-3,812,000USD-2,249,000USD-67,163,000USD-4,005,000USD-1,605,000USD-2,847,000USD-49,296,000USD
    Unclassified Operating Cash Flow-66,200,000USD-271,410,000USD-66,419,000USD-43,833,000USD—-64,404,000USD-75,183,000USD-66,385,001USD
    Unclassified Financing Cash Flow32,900,000USD—10,497,000USD11,447,000USD-357,245,000USD—3,190,000USD204,818,000USD
    Sale Purchase Of Stock—0USD-125,023,000USD—360,725,000USD-150,001,000USD-161,428,000USD-99,795,000USD
    Unclassified Investing Cash Flow—57,675,000USD668,017,000USD63,881,000USD13,287,000USD845,913,000USD257,091,000USD16,903,999USD
    Dividends Paid———————-112,279,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-356,148,000USD560,120,000USD414,832,000USD-224,060,000USD-329,668,000USD238,616,000USD523,367,000USD447,098,000USD
    Depreciation696,297,000USD660,067,000USD638,696,000USD629,471,000USD552,483,000USD278,253,000USD370,156,000USD216,731,000USD
    Stock Based Compensation291,133,000USD248,045,000USD226,841,000USD221,996,000USD189,006,000USD120,998,000USD110,563,000USD102,441,000USD
    Other Non Cash Items1,150,563,000USD212,723,000USD276,294,000USD926,916,000USD345,440,000USD484,155,000USD159,009,000USD98,163,000USD
    Change To Account Receivables-106,279,000USD-21,115,000USD-51,883,000USD-90,135,000USD-92,735,000USD-38,647,000USD-92,326,000USD-40,132,000USD
    Change To Inventory-86,041,000USD-45,542,000USD-13,420,000USD-49,642,000USD-48,861,000USD-30,537,000USD-32,790,000USD-18,512,000USD
    Change In Working Capital18,899,000USD-76,720,000USD-204,439,000USD9,905,000USD-47,952,000USD-85,437,000USD-150,084,000USD23,286,000USD
    Total Cash From Operating Activities1,355,773,000USD1,395,908,000USD1,092,007,000USD1,271,977,000USD778,507,000USD899,648,000USD776,401,000USD798,904,000USD
    Capital Expenditures-209,752,000USD-48,070,000USD-23,962,000USD-498,194,000USD-45,532,000USD-379,254,000USD-182,335,000USD-131,470,000USD
    Free Cash Flow1,146,021,000USD1,347,838,000USD1,068,045,000USD773,783,000USD732,975,000USD520,394,000USD594,066,000USD667,434,000USD
    Investments-470,275,000USD-508,195,000USD-589,238,000USD-1,036,000USD1,068,181,000USD-642,675,000USD-155,300,000USD-310,915,000USD
    Total Cashflows From Investing Activities-1,509,913,000USD-508,195,000USD-163,062,000USD-446,230,000USD-5,212,143,000USD-1,007,670,000USD-155,300,000USD-394,487,000USD
    Net Borrowings-781,000,000USD374,767,000USD-31,000,000USD-582,014,000USD3,870,863,000USD591,806,000USD-33,387,000USD-32,123,000USD
    Total Cash From Financing Activities-873,380,000USD20,516,000USD-305,254,000USD-529,491,000USD3,970,522,000USD528,073,000USD-293,745,000USD-479,130,000USD
    Sale Purchase Of Stock-125,023,000USD-311,429,000USD-269,761,000USD-54,000USD-35,602,000USD-146,537,000USD-301,450,000USD-523,672,000USD
    Change In Cash-1,020,965,000USD906,554,000USD624,828,000USD290,034,000USD-466,321,000USD420,425,000USD327,722,000USD-76,413,000USD
    Begin Period Cash Flow2,412,864,000USD1,506,310,000USD881,482,000USD591,448,000USD1,057,769,000USD637,344,000USD309,622,000USD386,035,000USD
    End Period Cash Flow1,391,899,000USD2,412,864,000USD1,506,310,000USD881,482,000USD591,448,000USD1,057,769,000USD637,344,000USD309,622,000USD
    Other Cashflows From Investing Activities-122,833,000USD-10,000,000USD-19,000,000USD-444,148,000USD-17,891,000USD378,509,000USD101,335,000USD-63,202,000USD
    Other Cashflows From Financing Activities-75,220,000USD-63,469,000USD-50,952,000USD52,577,000USD-35,602,000USD82,804,000USD41,092,000USD70,259,000USD
    Unclassified Operating Cash Flow-444,971,000USD-208,327,000USD-260,217,000USD-292,251,000USD69,198,000USD-136,937,000USD-236,610,000USD-88,815,000USD
    Unclassified Investing Cash Flow-707,053,000USD58,070,000USD469,138,000USD497,148,000USD-6,216,901,000USD-364,250,000USD81,000,000USD111,100,000USD
    Unclassified Financing Cash Flow107,863,000USD20,647,000USD46,459,000USD98,020,000USD270,522,000USD99,681,000USD57,831,000USD6,406,000USD
    Change To Liabilities———141,678,000USD54,716,000USD64,613,000USD-644,000USD83,050,000USD
    Dividends Paid———-98,020,000USD-99,659,000USD-99,681,000USD-57,831,000USD—
    Cash And Cash Equivalents Changes———296,256,000USD-463,114,000USD420,051,000USD—-76,413,000USD
    Exchange Rate Changes———————-1,700,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-06-30GeographyEurope97,400,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyOther Countries33,000,000USDDisclosure
    Q2 2026Quarterly · 2026-06-30GeographyUnited States1,077,900,000USDDisclosure
    Q1 2026Quarterly · 2026-03-31GeographyEurope92,400,000USD0001232524-26-000025
    Q1 2026Quarterly · 2026-03-31GeographyOther Countries16,700,000USD0001232524-26-000025
    Q1 2026Quarterly · 2026-03-31GeographyUnited States959,800,000USD0001232524-26-000025
    Q4 2025Quarterly · 2025-12-31GeographyEurope88,354,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyOther Countries32,674,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31GeographyUnited States1,076,939,000USDLegacy provider
    FY 2025Yearly · 2025-12-31GeographyEurope341,122,000USD0001232524-26-000013
    FY 2025Yearly · 2025-12-31GeographyOther Countries94,866,000USD0001232524-26-000013
    FY 2025Yearly · 2025-12-31GeographyUnited States3,831,598,000USD0001232524-26-000013
    Q3 2025Quarterly · 2025-09-30GeographyEurope86,405,000USD0001232524-25-000074
    Q3 2025Quarterly · 2025-09-30GeographyOther Countries19,226,000USD0001232524-25-000074
    Q3 2025Quarterly · 2025-09-30GeographyUnited States1,020,476,000USD0001232524-25-000074
    Q2 2025Quarterly · 2025-06-30GeographyEurope82,763,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30GeographyOther Countries26,666,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30GeographyUnited States936,283,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductDefitelio Defibrotide48,106,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductHigh Sodium AGOxybate Product Royalty Revenue54,138,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductOther Products256,138,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductOther Royalty And Contract Revenues6,003,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductRylaze Enrylaze100,659,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductSativex4,615,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductVyxeos44,851,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductXyrem35,349,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductXywav415,321,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductZepzelca74,541,000USD0001232524-25-000063
    Q2 2025Quarterly · 2025-06-30ProductZiihera5,991,000USD0001232524-25-000063
    Q1 2025Quarterly · 2025-03-31GeographyEurope83,600,000USD0001232524-26-000025
    Q1 2025Quarterly · 2025-03-31GeographyOther Countries16,300,000USD0001232524-26-000025
    Q1 2025Quarterly · 2025-03-31GeographyUnited States797,900,000USD0001232524-26-000025
    Q4 2024Quarterly · 2024-12-31GeographyEurope81,874,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyOther Countries32,665,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31GeographyUnited States973,634,000USDLegacy provider
    FY 2024Yearly · 2024-12-31GeographyEurope312,706,000USD0001232524-26-000013
    FY 2024Yearly · 2024-12-31GeographyOther Countries96,135,000USD0001232524-26-000013
    FY 2024Yearly · 2024-12-31GeographyUnited States3,660,109,000USD0001232524-26-000013
    Q3 2024Quarterly · 2024-09-30GeographyEurope77,318,000USD0001232524-25-000074
    Q3 2024Quarterly · 2024-09-30GeographyOther Countries23,982,000USD0001232524-25-000074
    Q3 2024Quarterly · 2024-09-30GeographyUnited States953,669,000USD0001232524-25-000074
    Q3 2024Quarterly · 2024-09-30ProductHigh Sodium AGOxybate Product Royalty Revenue58,157,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductOther Royalty And Contract Revenues7,105,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Defitelio Defibrotide65,818,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Epidiolex Epidyolex251,558,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Other Products2,229,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Rylaze Enrylaze98,780,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Sativex4,586,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Vyxeos34,313,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Xyrem58,114,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Xywav388,466,000USD0001232524-24-000086
    Q3 2024Quarterly · 2024-09-30ProductProduct And Services Product Sales Net Of Deductions — Zepzelca85,843,000USD0001232524-24-000086
    Q2 2024Quarterly · 2024-06-30ProductHigh Sodium AGOxybate Product Royalty Revenue54,164,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductOther Royalty And Contract Revenues5,517,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Defitelio Defibrotide45,421,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Epidiolex Epidyolex247,102,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Other Products2,698,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Rylaze Enrylaze107,829,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Sativex6,383,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Vyxeos43,012,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Xyrem62,180,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Xywav368,472,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductProduct And Services Product Sales Net Of Deductions — Zepzelca81,047,000USD0001232524-25-000063
    Q2 2024Quarterly · 2024-06-30ProductZiihera0USD0001232524-25-000063
    Q1 2024Quarterly · 2024-03-31ProductHigh Sodium AGOxybate Product Royalty Revenue49,947,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductOther Royalty And Contract Revenues9,934,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Defitelio Defibrotide47,676,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Epidiolex Epidyolex198,716,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Other Products3,570,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Rylaze Enrylaze102,750,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Sativex2,735,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Vyxeos32,023,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Xyrem64,232,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Xywav315,300,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductProduct And Services Product Sales Net Of Deductions — Zepzelca75,100,000USD0001232524-25-000027
    Q1 2024Quarterly · 2024-03-31ProductZiihera0USD0001232524-25-000027
    FY 2023Yearly · 2023-12-31GeographyEurope269,243,000USD0001232524-26-000013
    FY 2023Yearly · 2023-12-31GeographyOther Countries74,984,000USD0001232524-26-000013
    FY 2023Yearly · 2023-12-31GeographyUnited States3,489,977,000USD0001232524-26-000013
    Q2 2023Quarterly · 2023-06-30ProductHigh Sodium AGOxybate Product Royalty Revenue5,514,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductOther Royalty And Contract Revenues4,816,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Defitelio Defibrotide46,108,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Epidiolex Epidyolex202,226,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Other Products3,417,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Rylaze101,693,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Sativex2,806,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Vyxeos34,056,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Xyrem159,769,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Xywav326,564,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductProduct And Services Product Sales Net Of Deductions — Zepzelca70,348,000USD0001232524-23-000037
    Q2 2023Quarterly · 2023-06-30ProductSunosi0USD0001232524-23-000037
    Q1 2023Quarterly · 2023-03-31ProductHigh Sodium AGOxybate Product Royalty Revenue2,096,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductOther Royalty And Contract Revenues6,497,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Defitelio Defibrotide39,079,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Epidiolex Epidyolex188,909,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Other Products3,434,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Rylaze85,927,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Sativex7,098,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Vyxeos36,700,000USD0001232524-23-000026
    Q1 2023Quarterly · 2023-03-31ProductProduct And Services Product Sales Net Of Deductions — Xyrem178,130,000USD0001232524-23-000026

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.